

1

2

2

2

: (*in vitro*) ( $^1\text{H}$ ) (magnetic resonance spectroscopy: MRS)  
가

: 30  
( $n=12$ )

( $n=18$ ) ( $n=2$ ), ( $n=14$ ) 3가 ( $n=2$ ),

, ( $n=7$ ) ( $n=23$ )

lactate

$^1\text{H}$  MRS

1.5T

PRESS (point resolved spectroscopy)

(TR/TE=2000/30 msec)

( $\text{H}_2\text{O}$ )

MR

가

MR

: 30

lipid (0.9/1.3 ppm), lactate (1.3 ppm),

acetate (1.9 ppm),

succinate (2.4 ppm)

8가

( $n=12$ ) MR

pattern - 1 7 (58%),

pattern - 2가 2 (17%), pattern - 3 1 (8%), pattern - 6 1 (8%), pattern - 8 1 (8%)

( $n=18$ ) MR

pattern - 4가 1 (6%), pattern - 5가 5

(28%), pattern - 6 1 (6%), pattern - 7 3 (17%), pattern - 8 8 (44%)

( $p < .05$ ).

( $n=23$ ) MR

pattern - 1 7 (30%), pattern - 2가 2 (9%),

pattern - 3 1 (4%), pattern - 4가 1 (4%), pattern - 5가 3 (13%), pattern - 6 2

(9%), pattern - 7 1 (4%), pattern - 8 6 (26%) ( $n=7$ ) MR

pattern - 5가 2 (29%), pattern - 7 2 (29%), pattern - 8 3 (43%)

가 ( $p = .300$ ).

:

(computed tomography: CT)

(ascites)가

가

(1).

CT

가 (2-4).

<sup>1</sup>

<sup>2</sup>

2006 3 2

2006 5 29

:

가  
가 . MRS  
가 (23 - 25).  
(5). (magnetic resonance MRS가  
imaging: MRI) 가 (25).  
MRI <sup>1</sup>H MRS  
가 (1, 6 - 8). MRS 가  
Brown (6)  
, 가  
가  
30  
1970 , MRI (n=12)  
1980 , (n=18)  
MRI (n=2),  
(n=14) 3가  
가 9 , 2 ,  
(*in vivo*) (<sup>1</sup>H) (magnetic resonance  
spectroscopy: MRS) (9, 10). , MRI가  
(<sup>1</sup>H)  
MRS , 가 1 ,  
가 1 ,  
가 8 , 가 5 ,  
(11, 12). 가 1 ,  
MRS (n=23) (n=7)  
가  
MRS 가  
가 , lactate ,  
가 1.1  
(13 - 16). 1990 3 g/dL (transudate) ,  
(localization) (water - suppression) (exudate)  
(gradient shimming)  
MRS  
(17). 30 mL  
MRS 3 - 4 °C 24  
가  
3 2 3  
24  
(18 - 22).  
(*in vitro*) (<sup>1</sup>H MRS)  
MRS MR scanner 1.5T Signa Excite

Twinspeed MR Scanner (GE Healthcare, Milwaukee, U.S.A.)

(birdcage) zero - filling (Signal to  
 $^1\text{H}$  MRS ( , FID) Noise Ratio: SNR) 가 6 Hz Gaussian line  
 MR broadening filter

MR . SNR 5 가

(gel) . MRI ppm  
 $^1\text{H}$  MRS (volume of interest:  
 VOI) Fisher's exact test  
 . VOI Mann - Whitney U test  
 $4.5\text{ cm}^3$  (1.5 cm × 1.5 cm × 2 cm) (voxel)  
 $^1\text{H}$  MRS

MR (gantry) 가  
 (susceptibility) 30  
 3 가 (lipid) (0.9/1.3 ppm),  
 X, Y, Z (shimming coil) (lactate) (1.3 ppm), (acetate) (1.9 ppm),  
 (succinate) (2.4 ppm) 가 가

가 . 4  
 MR 가 8가  
 (Table 1).

가  
 PRESS (Point Resolved Spectroscopy) MR  
 64 MR  
 (H<sub>2</sub>O) 3  
 (Chemical Shift Selective Saturation: lipid, lactate, acetate, succinate  
 CHESS) .  $^1\text{H}$  MRS , 24

matrix  $256 \times 256$ , (number of excitation: NEX) 3  
 8, (time to repetition: TR) 2,000 msec, 2 24 lipid, lactate,  
 (time to echo: TE) 30 msec, (spectral width) acetate, succinate  
 2,500 Hz, (number of data point) 2,048 .

2 56  
 MR  
 MR lactate 가 17 (57%)  
 13 (43%) (Table 2). Lactate

MR PRESS (Free  
 Induction Decay: FID) SAGE™ data analysis  
 package (GE Healthcare, Milwaukee, U.S.A.)

가 (Gaussian) (filtering)  
 (Fourier)

MR .  
 (phasing) (baseline correction)

MR 가

0 (zero order)  
 가 1 (first order)

**Table 1.** Classification of MR Spectral Patterns


MR Spectral Pattern	Resonance Detected			
	Succinate	Acetate	Lactate	Lipid
1	Yes	Yes	Yes	Yes
2	Yes	Yes	Yes	No
3	No	Yes	Yes	Yes
4	No	Yes	No	Yes
5	No	No	Yes	Yes
6	No	No	Yes	No
7	No	No	No	Yes
8	No	No	No	No

:

가 lactate 9.11 ± 9.42  
 mmol/L lactate 가 12 가 8 (67%)  
 1.65 ± 1.63 mmol/L 4 (33%) . Lactate 12 ± 9.9 mmol/L  
 (p < .05) (Table 3).  
 6  
 (Enterococcus faecalis) 1 ,

**Table 2.** MR Spectral Patterns for Abdominal Fluid Samples

No.	Resonance Detected				MR Spectral Pattern
	Succinate	Acetate	Lactate	Lipid	
1	Yes	Yes	Yes	Yes	1
2	Yes	Yes	Yes	Yes	1
3	Yes	Yes	Yes	Yes	1
4	Yes	Yes	Yes	No	2
5	Yes	Yes	Yes	Yes	1
6	Yes	Yes	Yes	No	2
7	No	Yes	Yes	Yes	3
8	Yes	Yes	Yes	Yes	1
9	Yes	Yes	Yes	Yes	1
10	Yes	Yes	Yes	Yes	1
11	No	No	Yes	No	6
12	No	No	No	No	8
13	No	Yes	No	Yes	4
14	No	No	Yes	Yes	5
15	No	No	Yes	No	6
16	No	No	Yes	Yes	5
17	No	No	Yes	Yes	5
18	No	No	Yes	Yes	5
19	No	No	No	Yes	7
20	No	No	No	Yes	7
21	No	No	No	No	8
22	No	No	No	No	8
23	No	No	No	No	8
24	No	No	No	No	8
25	No	No	No	No	8
26	No	No	No	No	8
27	No	No	No	Yes	7
28	No	No	Yes	Yes	5
29	No	No	No	No	8
30	No	No	No	No	8




**Fig. 1.** Comparison of the MR spectral patterns between purulent abdominal fluid (A) and non-purulent abdominal fluid (B).

(*Enterobacter cloacae*) 1, (*Enterococcus* (75%) . MR pattern - 1  
*avium*) 2, (*Mycobacterium tuberculosis*) 1, 7 (58%), pattern - 2† 2 (17%), pattern - 3 1 (8%),  
(*Bacteroides fragilis*) 1, pattern - 6 1 (8%), pattern - 8 1 (8%) (Figs. 1A,  
3) (Table 2).  
MR lipid 8 (67%), lactate 11  
(92%), acetate 10 (83%), succinate 9 ( $p < .05$ ).

**Table 3.** Data for Abdominal Fluid Samples

No.	Gross Finding	Cause	Transudate / Exudate	Benign / Malignant	Lactate (mmol/L)	Culture
1	Purulent	Post-operative	Exudate	Benign	7.8	<i>E. faecalis</i>
2	Purulent	Post-operative	Exudate	Benign	8.3	<i>E. cloacae</i>
3	Purulent	Post-operative	Exudate	Benign	6.5	
4	Purulent	Post-operative	Exudate	Benign	12.9	
5	Purulent	Post-operative	Transudate	Benign	13	
6	Purulent	Post-operative	Transudate	Benign	7.3	
7	Purulent	Liver Abscess	Exudate	Benign	12	
8	Purulent	Post-operative	Transudate	Benign	7	<i>E. avium</i>
9	Purulent	Liver Abscess	Exudate	Benign	42.5	<i>B. fragilis</i>
10	Purulent	Post-operative	Exudate	Benign	8.8	<i>E. avium</i>
11	Purulent	Psoas Abscess	Exudate	Benign	11.2	<i>M. tuberculosis</i>
12	Purulent	Post-operative	Transudate	Benign	6.8	
13	Bloody	Liver injury	Exudate	Benign	2.4	
14	Bloody	Kidney injury	Exudate	Benign	3.2	
15	Clear with debris	Post-operative	Transudate	Benign	4.4	
16	Clear with debris	SBP	Exudate	Benign	5.4	<i>E. faecium</i>
17	Clear	Post-operative	Transudate	Malignant	1.1	
18	Clear	Post-operative	Exudate	Malignant	1.2	
19	Clear	Post-operative	Transudate	Malignant	1.8	
20	Clear	Post-operative	Transudate	Malignant	1.1	
21	Clear	Liver Cirrhosis	Transudate	Benign	0.8	
22	Clear	Post-operative	Transudate	Benign	1.5	
23	Clear	Liver cirrhosis	Transudate	Benign	0.8	
24	Clear	Post-operative	Exudate	Malignant	0.6	
25	Clear	Post-operative	Exudate	Malignant	1.3	
26	Clear	Liver cirrhosis with HCC	Exudate	Malignant	1.5	
27	Clear	Liver Cirrhosis	Transudate	Benign	1.3	
28	Clear	Post-operative	Transudate	Benign	2.2	
29	Clear	Liver cirrhosis	Transudate	Benign	0.6	
30	Clear	Liver cirrhosis	Transudate	Benign	0.9	


Note.—SBP = spontaneous bacterial peritonitis. HCC = hepatocellular carcinoma.

**Fig. 2.** Comparison of the MR spectral patterns between benign abdominal fluid (A) and malignant abdominal fluid (B).


:

( $p < .05$ ).

18	가	7 (39%)			
11 (61%)	. Lactate	1.8 ± 1.33			
mmol/L	가	7 (39%)			
	11 (61%)	1	2.4, 3.2 mmol/L	. Lactate	2
Enterococcus faecium	(Table 3).		(Table 3).		
MR	lipid	9 (50%), lactate	6	MR	lipid
(33%), acetate	1 (6%)	succinate	1 (50%), acetate	1 (50%)	2 (100%), lactate
	. MR		succinate	2	. MR
pattern - 47† 1 (6%), pattern - 57† 5 (28%), pattern - 6			pattern - 47† 1 (50%), pattern - 57† 1 (50%)		
1 (6%), pattern - 7 3 (17%), pattern - 8 8 (44%)			(Fig. 4) (Table 2).		
(Figs. 1B, 4 - 6) (Table 2).					




**Fig. 3.** Purulent and benign fluid in a 71-year-old man who underwent an operation for appendicitis. CT scan (A) shows an abscess (arrow) with internal air-fluid level and enhancing wall in RLQ of abdomen. MR spectrum (B) shows the metabolite peaks assigned to lipid (0.9/1.3 ppm), lactate (1.3 ppm), acetate (1.9 ppm), and succinate (2.4 ppm) (pattern-1).




**Fig. 4.** Hemorrhagic and benign fluid in a 24-year-old man with blunt liver trauma. CT scan (A) shows hepatic laceration and ascites (arrows) in right subhepatic space and perisplenic space. MR spectrum (B) shows the metabolite peaks assigned to lipid (0.9/1.3 ppm) and lactate (1.3 ppm) (pattern-5).

		2 가		(29%)	10 (71%)	. Lactate		
1	. Lactate	4.4	5.4 mmol/L	1.2 ± 0.46 mmol/L	.	가	7	
2	Enterococcus faecium	(Table 3).		(50%)	7 (50%)	.		
MR	lipid	1 (50%), lactate	2	MR	lipid	6 (43%), lactate	3	
	acetate	succinate	2	(21%)	acetate	succinate		
	. MR	pattern - 5	57	3 (21%), pattern - 7	3 (21%), pattern - 8	8		
가 1	(50%), pattern - 6	1 (50%) (Fig. 5) (Table 2).		(57%) (Fig. 6) (Table 2).				

14 가 4 (n=23) 11 (48%) 12  
 (52%) . Lactate 7.29 ± 8.69 mmol/L



**Fig. 5.** Serosanguinous fluid with debris and benign fluid in a 63-year-old man who underwent an operation for cholecystitis. CT scan (A) shows ascites (arrows) in pelvic cavity. MR spectrum (B) shows the metabolite peak assigned to lactate (1.3 ppm) (pattern-6).



**Fig. 6.** Serosanguinous fluid without debris and malignant fluid in a 57-year-old man who underwent an operation for colon cancer. CT scan (A) shows ascites (arrows) in both paracolic gutters. MR spectrum (B) shows the metabolite peaks assigned to lipid (0.9/1.3 ppm) and lactate (1.3 ppm) (pattern-5).

:

. Enterococcus faecalis가 1 , Enterobacter cloacae가 1 , Enterococcus avium 2 , Mycobacterium tuberculosis가 1 , Enterococcus faecium 1 , Bacteroides fragilis가 1 (Table 3).

MR lipid 13 (57%), lactate 15 (65%), acetate 11 (48%), succinate 9 (39%). MR pattern - 1 7 (30%), pattern - 2가 2 (9%), pattern - 3 1 (4%), pattern - 4가 1 (4%), pattern - 5가 3 (13%), pattern - 6 2 (9%), pattern - 7 1 (4%), pattern - 8 6 (26%) (Figs. 2A, 3-5) (Table 2).

가 ( $p = .300$ ).

( $n=7$ ) 4 (57%) 3 (43%) . Lactate 1.23  $\pm$  0.37 mmol/L (Table 3). MR lipid 4 (57%), lactate 2 (29%) acetate succinate . MR pattern - 5가 2 (29%), pattern - 7 2 (29%), pattern - 8 3 (43%) (Figs. 2B, 6) (Table 2).

가 ( $p = .300$ ).

. MRI

. MRI T1 T2

(1, 6-8)가

, 가 . Cohen (1) T2

, T1 T2 T1 , T1

가 T1 (26), 가

T1

가 .

1980

MRS

가

,

MRS

MRS

(10).

$^1\text{H}$  MRS

,

가

1.5T

가

8 cm<sup>3</sup>

$^1\text{H}$  MRS

MRI

$^1\text{H}$  MRS

(13).

$^1\text{H}$  MRS

(chemical shift)

MR

M)

(10 mM)

STEAM)

$^1\text{H}$  MRS가

TE

MRS

Poptani (33) 7 lactate (1.3 ppm), alanine (1.5 ppm), acetate (1.9 ppm), (0.9 ppm)

5 lactate, acetate, alanine, valine leucine (0.9 ppm) succinate (2.4 ppm)

succinate가

(fermentation)

(19)

(18-22).

(31-34).

lactate (1.3 ppm), alanine (1.5 ppm), acetate (1.9 ppm), (0.9 ppm)

. Remy (34)

lactate, acetate, alanine, (0.9 ppm)

lactate, acetate, (35-38).

(glycolysis)

. Grand

MR

가

가

MRS



MRS (23 - 25). , 1.0 ppm valine leucine, isoleucine 가 .  
 Burn (25) .  
 MRS , 1.3 ppm (doublet) SNR , 0.2 - 2.5 ppm 1.5 ppm TE=144 msec lactate - 180 ° 가 , lipid lactate 가 (34). TE 30 msec 0.9 ppm lipid .  
 Burn (25) .  
 12 가 lactate, acetate, succinate 가 11 (92%), 10 (83%), 9 (75%) 가 .  
 30 , MR ,  
 'H MRS , 가 (chylous fluid) 가 가 가 가 lactate, acetate, succinate 8가 .  
 0.9 ppm 1.3 ppm 가 . Grand (19) 0.9 ppm valine, leucine, isoleucine pattern - 5

1. Cohen JM, Weinreb JC, Maravilla KR. Fluid collections in the intraperitoneal and extraperitoneal spaces: comparison of MR and CT. *Radiology* 1985;155:705-708
2. Bydder GM, Kreel L. Attenuation values of fluid collections within the abdomen. *J Comput Assist Tomogr* 1980;4:145-150
3. Jolles H, Coulam CM. CT of ascites: differential diagnosis. *AJR Am J Roentgenol* 1980;135:315-322
4. Callen PW. Computed tomographic evaluation of abdominal and pelvic abscesses. *Radiology* 1979;131:171-175
5. Thrall JH, Ziessman HA. *Infection and inflammation*. In Thrall JH, Ziessman HA. *Nuclear medicine: the requisites*. 2nd ed. St Louis: Mosby, 2001;167-192
6. Brown JJ, vanSonnenberg E, Gerber KH, Strich G, Wittich GR, Slutsky RA. Magnetic resonance relaxation times of percutaneously obtained normal and abnormal body fluids. *Radiology* 1985;154:727-731
7. Wall SD, Hricak H, Bailey GD, Kerlan RK Jr, Goldberg HI, Higgins CB. MR imaging of pathologic abdominal fluid collections. *J Comput Assist Tomogr* 1986;10:746-750
8. Loflin TG, Simeone JF, Mueller PR, Saini S, Stark DD, Butch RJ, et al. Gallbladder bile in cholecystitis: in vitro MR evaluation. *Radiology* 1985;157:457-459
9. Matson GB, Weiner MW. *Spectroscopy*. In Stark DD, Bradley WG Jr. *Magnetic Resonance Imaging*. 3rd ed. St. Louis: Mosby, 1999;181-214
10. Bolinger L, Insko EK. *Spectroscopy: basic principles and techniques*. In Edelman RR, Hesselink JR, Zlatkin MB. *Clinical Magnetic Resonance Imaging*. 2nd ed. Philadelphia: W. B. Saunders, 1996;928-981
11. Ross BD. The biochemistry of living tissues: examination by MRS. *NMR Biomed* 1992;5:215-219
12. Cousins JP. Clinical MR spectroscopy: fundamentals, current applications, and future potential. *AJR Am J Roentgenol* 1995;164:1337-1347
13. Howe FA, Maxwell RJ, Saunders DE, Brown MM, Griffiths JR. Proton spectroscopy in vivo. *Magn Reson Q* 1993;9:31-59
14. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. *Magn Reson Q* 1994;10:191-247

15. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HB. In vivo quantification of brain metabolites by <sup>1</sup>H MRS using water as an internal standard. *Magn Reson Imaging* 1993;11:107-118
16. Sonnewald U, Gribbestad IS, Westergaard N, Nilsen G, Unsgard G, Schousboe A, et al. Nuclear magnetic resonance spectroscopy: biochemical evaluation of brain function in vivo and in vitro. *Neurotoxicology* 1994;15:579-590
17. . (Magnetic Resonance Spectroscopy). 1997;1:1-31
18. Lai PH, Ho JT, Chen WL, Hsu SS, Wang JS, Pan HB, et al. Brain abscess and necrotic brain tumor: discrimination with proton MR spectroscopy and diffusion-weighted imaging. *AJNR Am J Neuroradiol* 2002;23:1369-1377
19. Grand S, Passaro G, Ziegler A, Esteve F, Boujet C, Hoffmann D, et al. Necrotic tumor versus brain abscess: importance of amino acids detected at <sup>1</sup>H MR spectroscopy-initial results. *Radiology* 1999;213:785-793
20. Dev R, Gupta RK, Poptani H, Roy R, Sharma S, Husain M. Role of in vivo proton magnetic resonance spectroscopy in the diagnosis and management of brain abscesses. *Neurosurgery* 1998;42:37-42
21. Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. *Neuroradiology* 2002;44:371-381
22. Shukla-Dave A, Gupta RK, Roy R, Husain N, Paul L, Venkatesh SK, et al. Prospective evaluation of in vivo proton MR spectroscopy in differentiation of similar appearing intracranial cystic lesions. *Magn Reson Imaging* 2001;19:103-110
23. Le Moyec L, Racine S, Le Toumelin P, Adnet F, Larue V, Cohen Y, et al. Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. *Crit Care Med* 2002;30:1242-1245
24. Godet C, Hira M, Adoun M, Eugene M, Robert R. Rapid diagnosis of alcoholic ketoacidosis by proton NMR. *Intensive Care Med* 2001;27:785-786
25. Burn PR, Haider MA, Alfuhaid T, Brown MP, Roberts TP. Proton magnetic resonance spectroscopy as a potential tool for differentiating between abdominal fluid collections. *J Magn Reson Imaging* 2003;18: 740-744
26. Stark DD, Moss AA, Goldberg HI, Davis PL, Federle MP. Magnetic resonance and CT of the normal and diseased pancreas: a comparative study. *Radiology* 1984;150:153-162
27. Ross B, Kreis R, Ernst T. Clinical tools for the 90s: magnetic resonance spectroscopy and metabolite imaging. *Eur J Radiol* 1992;14:128-140
28. Henriksen O. MR spectroscopy in clinical research. *Acta Radiol* 1994;35:96-116
29. Westbrook C. *Handbook of MRI Technique*. Oxford: Blackwell Science, 1994;15-26
30. Bottomley PA. Human in vivo NMR spectroscopy in diagnostic medicine: clinical tool or research probe? *Radiology* 1989;170:1-15
31. Demaerel P, Van Hecke P, Van Oostende S, Baert AL, Jaeken J, Declercq PE, et al. Bacterial metabolism shown by magnetic resonance spectroscopy. *Lancet* 1994;344:1234-1235
32. Harada M, Tanouchi M, Miyoshi H, Nishitani H, Kannuki S. Brain abscess observed by localized proton magnetic resonance spectroscopy. *Magn Reson Imaging* 1994;12:1269-1274
33. Poptani H, Gupta RK, Jain VK, Roy R, Pandey R. Cystic intracranial mass lesions: possible role of in vivo MR spectroscopy in its differential diagnosis. *Magn Reson Imaging* 1993;11:443-449
34. Remy C, Grand S, Lai ES, Belle V, Hoffmann D, Berger F, et al. <sup>1</sup>H MRS of human brain abscesses in vivo and in vitro. *Magn Reson Med* 1995;34:508-514.
35. Phillips KD, Tearle PV, Willis AT. Rapid diagnosis of anaerobic infections by gas-liquid chromatography of clinical material. *J Clin Pathol* 1976;29:428-432
36. Deacon AG, Duerden BI, Holbrook WP. Gas-liquid chromatographic analysis of metabolic products in the identification of bacteroidaceae of clinical interest. *J Med Microbiol* 1977;11:81-99
37. Gorbach SL, Mayhew JW, Bartlett JG, Thadepalli H, Onderdonk AB. Rapid diagnosis of anaerobic infection by direct gas-liquid chromatography of clinical specimens. *J Clin Invest* 1976;57:478-484
38. Onderdonk AB, Sasser M. *Gas-liquid and high performance liquid chromatographic methods for the identification of microorganisms*. In Murray PR. *Manual of clinical microbiology*. 6th ed. Washington, DC: ASM Press, 1995;123-128

## The Usefulness of *In Vitro* Proton Magnetic Resonance Spectroscopy for Differentiating Between Abdominal Body Fluids<sup>1</sup>

Jeong Won Oh, M.D., Sang Soo Shin, M.D., Yong Yeon Jeong, M.D.<sup>2</sup>, Sang Gook Song, M.D.,  
Hyo Soon Lim, M.D.<sup>2</sup>, Hyun Ju Seon, M.D., Jae Kyu Kim, M.D.,  
Gwang Woo Jeong, M.D., Heoung Keun Kang, M.D.<sup>2</sup>

<sup>1</sup>Department of Diagnostic Radiology, Chonnam National University Hospital

<sup>2</sup>Department of Diagnostic Radiology, Chonnam National University Hwasun Hospital

**Purpose:** The purpose of this study was to determine whether *in vitro* proton (<sup>1</sup>H) magnetic resonance spectroscopy (MRS) is useful for distinguishing between abdominal types of fluids.

**Materials and Methods:** Thirty fluid samples that were obtained from patients who were undergoing diagnostic or therapeutic percutaneous drainage of abdominal fluids were examined in this study. According to their gross appearance and smell, each sample was classified as either purulent fluid (*n* = 12) or non-purulent fluid (*n* = 18). The non-purulent fluids were subdivided into hemorrhagic fluid (*n* = 2), serosanguinous fluid with debris (*n* = 2), and serosanguinous fluid without debris (*n* = 14). In addition, according to the cytologic analysis, each sample was classified as either benign fluid (*n* = 23) or malignant fluid (*n* = 7). A set of humoral pathological examinations that included biochemical analysis and culture of the fluid were performed for all the fluid samples. *In vitro* <sup>1</sup>H MRS was performed by using a 1.5T MR system and a birdcage head coil. MR spectra were obtained by using point-resolved spectroscopy (PRESS) (TR/TE = 2000/30 msec) with water suppression. The MR spectra were analyzed on the basis of agreement between a radiologist and a physicist who worked in consensus.

**Results:** The MR spectra obtained from 30 samples could be classified into 8 different patterns, according to the presence of lipid (0.9/1.3 ppm), lactate (1.3 ppm), acetate (1.9 ppm), and succinate (2.4 ppm) peaks. The MR spectral patterns of the purulent fluids (*n* = 12) were classified as follows: pattern-1 (*n* = 7, 58%), pattern-2 (*n* = 2, 17%), pattern-3 (*n* = 1, 8%), pattern-6 (*n* = 1, 8%) and pattern-8 (*n* = 1, 8%). The MR spectral patterns of the non-purulent fluids (*n* = 18) were classified as follows: pattern-4 (*n* = 1, 6%), pattern-5 (*n* = 5, 28%), pattern-6 (*n* = 1, 6%), pattern-7 (*n* = 3, 17%) and pattern-8 (*n* = 8, 44%). The MR spectral patterns of the purulent fluids were significantly different from those of the non-purulent fluids (*p* < .05). The MR spectral patterns of benign fluids (*n* = 23) were classified as follows: pattern-1 (*n* = 7, 30%), pattern-2 (*n* = 2, 9%), pattern-3 (*n* = 1, 4%), pattern-4 (*n* = 1, 4%), pattern-5 (*n* = 3, 13%), pattern-6 (*n* = 2, 9%), pattern-7 (*n* = 1, 4%) and pattern-8 (*n* = 6, 26%). The MR spectral patterns of malignant fluids (*n* = 7) were classified as follows: pattern-5 (*n* = 2, 29%), pattern-7 (*n* = 2, 29%) and pattern-8 (*n* = 3, 43%). No significant difference was found between the spectral patterns of the benign and malignant fluids (*p* = .300).

**Conclusion:** *In vitro* <sup>1</sup>H MRS could be useful for differentiating between purulent fluid and non-purulent fluid.

**Index words :** Magnetic resonance(MR), spectroscopy

Abscess

Abdomen, abscess

Address reprint requests to : Sang Soo Shin, M.D., Department of Diagnostic Radiology, Chonnam National University Hospital  
8 Hack-dong, Dong-gu, Gwangju, 501-757, Korea  
Tel. 82-62-220-5746 Fax. 82-62-226-4380 E-mail : kjradsss@dreamwiz.com